Compare AMPY & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMPY | BNR |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 246.9M | 252.7M |
| IPO Year | 2011 | 2019 |
| Metric | AMPY | BNR |
|---|---|---|
| Price | $6.22 | $16.09 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 29.4K |
| Earning Date | 05-11-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 232.26 | N/A |
| EPS | ★ 1.03 | N/A |
| Revenue | ★ $208,637,000.00 | N/A |
| Revenue This Year | N/A | $111.65 |
| Revenue Next Year | $14.60 | N/A |
| P/E Ratio | $6.01 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.27 | $2.18 |
| 52 Week High | $6.79 | $41.72 |
| Indicator | AMPY | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 52.90 | 35.45 |
| Support Level | $5.04 | $15.61 |
| Resistance Level | $6.71 | $23.42 |
| Average True Range (ATR) | 0.32 | 1.24 |
| MACD | -0.07 | 0.07 |
| Stochastic Oscillator | 38.38 | 4.17 |
Amplify Energy Corp is an independent oil and natural gas company engaged in the acquisition, development, exploitation, and production of oil and natural gas properties in the United States. The company's oil and natural gas properties are located in large, mature oil and natural gas reservoirs. The company assets consists of producing oil and natural gas properties located in Oklahoma, the Rockies, federal waters offshore Southern California, East Texas/North Louisiana and Eagle Ford.
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.